JP2018524575A5 - - Google Patents

Download PDF

Info

Publication number
JP2018524575A5
JP2018524575A5 JP2017565057A JP2017565057A JP2018524575A5 JP 2018524575 A5 JP2018524575 A5 JP 2018524575A5 JP 2017565057 A JP2017565057 A JP 2017565057A JP 2017565057 A JP2017565057 A JP 2017565057A JP 2018524575 A5 JP2018524575 A5 JP 2018524575A5
Authority
JP
Japan
Prior art keywords
seq
disease
citrullinated peptide
chronic neurodegenerative
mass spectrometry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017565057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524575A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/038439 external-priority patent/WO2016205828A2/en
Publication of JP2018524575A publication Critical patent/JP2018524575A/ja
Publication of JP2018524575A5 publication Critical patent/JP2018524575A5/ja
Pending legal-status Critical Current

Links

JP2017565057A 2015-06-18 2016-06-20 疾患の診断におけるシトルリン化の役割 Pending JP2018524575A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562181665P 2015-06-18 2015-06-18
US62/181,665 2015-06-18
US201562233231P 2015-09-25 2015-09-25
US62/233,231 2015-09-25
US201562387149P 2015-12-23 2015-12-23
US62/387,149 2015-12-23
PCT/US2016/038439 WO2016205828A2 (en) 2015-06-18 2016-06-20 Role of citrullination in diagnosing diseases

Publications (2)

Publication Number Publication Date
JP2018524575A JP2018524575A (ja) 2018-08-30
JP2018524575A5 true JP2018524575A5 (enExample) 2019-07-25

Family

ID=57546510

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017565057A Pending JP2018524575A (ja) 2015-06-18 2016-06-20 疾患の診断におけるシトルリン化の役割

Country Status (5)

Country Link
US (1) US11105817B2 (enExample)
EP (1) EP3311176A4 (enExample)
JP (1) JP2018524575A (enExample)
CN (1) CN107923917A (enExample)
WO (1) WO2016205828A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10309974B2 (en) 2010-11-12 2019-06-04 Cedars-Sinai Medical Center Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
US11105817B2 (en) 2015-06-18 2021-08-31 Cedars-Sinai Medical Center Role of citrullination in diagnosing diseases
JP2021503610A (ja) 2017-11-16 2021-02-12 ブレインボックス ソルーションズ、インコーポレイテッドBrainbox Solutions, Inc. 神経損傷および/または疾患のタンパク質バイオマーカー指標及びその使用の方法
JP7737900B2 (ja) * 2019-09-17 2025-09-11 キッコーマン株式会社 シトルリンの定量方法、定量用組成物、定量用キット、センサーチップ、センサー、及びペプチジルアルギニンデイミナーゼの活性評価方法
CN114839364B (zh) * 2022-04-27 2025-09-12 珠海丽珠试剂股份有限公司 抗突变型瓜氨酸化波形蛋白抗体检测试剂盒及其应用
EP4609859A1 (en) * 2024-02-28 2025-09-03 Universidad Pablo de Olavide Inhibitors of the gene smpd1 for the treatment of spinal muscular atrophy
CN118001407B (zh) * 2024-04-02 2024-06-21 北京大学人民医院 Pad2在制备治疗缺血缺氧性恶性心律失常药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047518A1 (en) 1999-12-23 2001-07-05 Childrens Hospital Los Angeles Research Institute Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant emap ii
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
US20040265849A1 (en) 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
SI1721162T1 (sl) 2004-02-27 2009-02-28 Roche Diagnostics Gmbh Postopek za ugotavljanje revmatoidnega artritisa z merjenjem anti-CCP in serumskega amiloida A
US20070148704A1 (en) 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
JP5305259B2 (ja) * 2007-12-25 2013-10-02 地方独立行政法人東京都健康長寿医療センター 抗シトルリン化gfapモノクローナル抗体及びその用途
GB0803107D0 (en) 2008-02-20 2008-03-26 Axis Shield Diagnostics Ltd Method
WO2010048388A1 (en) 2008-10-22 2010-04-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunoassays for citrullinated proteins
AU2010224175A1 (en) 2009-03-10 2011-09-29 Duke University Predicting coronary artery disease and risk of cardiovascular events
IL225538A0 (en) 2009-03-30 2013-06-27 Nestec Sa Methods for the identification of anti-immune reaction peptides of anti-citrullinates
US10309974B2 (en) 2010-11-12 2019-06-04 Cedars-Sinai Medical Center Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
US20140308676A1 (en) * 2010-11-12 2014-10-16 Justyna P. Fert-Bober Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
GB201213012D0 (en) * 2012-07-23 2012-09-05 Univ Warwick Diagnostic for determining skelektal health
WO2014037911A1 (en) * 2012-09-10 2014-03-13 Koninklijke Philips N.V. System and method for estimating susceptibility to a medical condition
JP6365863B2 (ja) * 2013-07-16 2018-08-01 国立大学法人 熊本大学 質量分析におけるペプチドピークの同定・定量のためのデータベース作成方法
US11105817B2 (en) 2015-06-18 2021-08-31 Cedars-Sinai Medical Center Role of citrullination in diagnosing diseases

Similar Documents

Publication Publication Date Title
CN106574930B (zh) 评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法
CN108027376B (zh) 评价脑内的淀粉样蛋白β蓄积状态的多重生物标记物及其分析方法
EP2502999A3 (en) Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
JP2021505844A5 (enExample)
JP2018500924A5 (enExample)
US20210109114A1 (en) Diagnostic method for multiple sclerosis
Simmons et al. TSPO–PET imaging using [18F] PBR06 is a potential translatable biomarker for treatment response in Huntington’s disease: preclinical evidence with the p75NTR ligand LM11A-31
JP2010187674A5 (enExample)
JP2012530055A5 (enExample)
JP2012522754A5 (enExample)
JP2016524592A5 (enExample)
JP2009544284A5 (enExample)
JP2018534236A5 (enExample)
JP2018516849A5 (enExample)
Zhao et al. A fluorescent molecular imaging probe with selectivity for soluble tau aggregated protein
JP2018535921A5 (enExample)
WO2012149334A2 (en) Methods and compositions for the generation and use of conformation-specific antibodies
DE69830588D1 (de) Diagnose und behandlung von krankheiten mittels anti-t-zell rezeptor-vbeta-antikörper oder peptide, an denen diese antikörper spezifisch binden, und esrp1
JP2025512827A (ja) 抗体、融合タンパク質及びその使用
JP2007526759A5 (enExample)
US20130171066A1 (en) Polymeric complements to a b-amyloid peptides
JP2012513584A5 (enExample)
Levin et al. Autoantibodies to heterogeneous nuclear ribonuclear protein A1 (hnRNPA1) cause altered ‘ribostasis’ and neurodegeneration; the legacy of HAM/TSP as a model of progressive multiple sclerosis
JP2017007990A (ja) アミロイド凝集性評価用汎用性量子ドットナノプローブ
KR102328709B1 (ko) 저분자 아밀로이드 베타 검출용 펩타이드 및 이의 용도